Nymox Pharmaceutical Corporation

… working to introduce a new, safe, efficacious and long-lasting therapy to the millions of men suffering from an enlarged prostate gland (BPH).

About us

The team behind Nymox Pharmaceuticals Corporation.

Science

Ongoing research for Fexapotide in BPH and low-grade localized prostate cancer

Upcoming Events

Coming soon

Fexapotide for BPH

For the treatment of Benign Prostate Hyperplasia (BPH)

Scientific Publications

Recent scientific publications featuring Fexapotide Triflutate

Press releases

March 21, 2023
Nymox Announces Appointment of Christopher R. Riley as Chief Financial Officer

More